
    
      Experimental plan

      Phase II controled study, in 40 patients, randomised in single blind, and in 2 groups:

        -  One group treated by transdermal nicotine-therapy (N= 20),

        -  One group without additional therapy (N= 20).

      This study will consist in :

        -  One phase of weekly incrementations of dose during 11 weeks,

             -  Steps of 5 mg until 20 mg

             -  Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose

        -  One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks,

        -  One phase of decrementing: treatment will be progressively decreased in a 6 weeks
           period,
    
  